• English
  • Korean
  • Chinese
市場調査レポート - 230864

米国のドラッグデリバリーシステム市場(〜2015年)

Drug Delivery Products (US Market & Forecast)

発行 Freedonia Group
出版日 ページ情報 英文 337 Pages
価格
米国のドラッグデリバリーシステム市場(〜2015年) Drug Delivery Products (US Market & Forecast)
出版日: 2012年02月06日 ページ情報: 英文 337 Pages
概要

米国のドラッグデリバリー製品需要は今後、年率7.4%で拡大し、2015年には1340億米ドルへ成長する見込みです。

当レポートでは、米国におけるドラッグデリバリー市場の現状と見通しについて調査分析し、市場実績(2000年・2005年・2010年)および予測(2015年・2020年)データを、賦形剤、製品タイプ、アプリケーション別に提供しており、市場影響因子、産業構造、市場シェア、主要企業27社のプロファイルなどをまとめ、概略以下の構成でお届けいたします。

イントロダクション

第1章 エグゼクティブサマリー

第2章 市場環境

  • 概要
  • 経済的要因
  • 人口統計パターン
  • ヘルスケア動向
  • 製薬市場の概要

第3章 ドラッグデリバリー賦形剤

  • 概要
  • ポリマー
    • ポリエチレングリコール
    • アクリルポリマー
    • ポリエチレンオキシド
    • ポリビニルアルコール
    • その他の合成ポリマー
  • セルロース賦形剤
    • エチルセルロース
    • ヒドロキシプロピルメチルセルロース
    • その他のセルロース賦形剤
  • ミネラル
    • ミネラル炭化水素
    • その他のミネラル
  • その他の賦形剤
    • 滅菌水・精製水
    • でんぷん複合物
    • 砂糖・ポリオール
    • 天然ガム
    • その他の賦形剤

第4章 ドラッグデリバリー製品の概要

  • 概要
  • 吸入
  • 埋め込み型
  • 規制
  • 研究開発
  • 米国の貿易
  • 国際市場

第5章 経口ドラッグデリバリー製品

  • 概要
  • 制御放出製剤
  • チュアブルタブレット
  • ナノ粒子製剤
  • (ODT)
  • 経粘膜製剤

第6章 非経口ドラッグデリバリー製品

  • 概要
  • 治療用モノクロナール抗体
  • カプセル型非経口ドラッグデリバリー製品
  • 注入製品
  • 非経口ドラッグデリバリー装置

第7章 その他のドラッグデリバリー製品

  • 概要
  • 吸入ドラッグデリバリー製品
  • 埋め込み型ドラッグデリバリー製品
  • 経皮ドラッグデリバリー製品

第8章 アプリケーション

  • 概要
  • 中枢神経系薬
  • 呼吸器系薬
  • ホルモン・関連医薬品
  • 胃腸薬
  • 心臓血管薬
  • 抗感染薬
  • 栄養剤
  • 泌尿生殖器薬
  • その他の医薬品

第9章 産業構造

  • 概要
  • 市場シェア
  • 競合戦略
  • M&A
  • ライセンス供与・関連合意
  • マーケティング・流通
  • 製造

企業プロファイル

図表

目次

Abstract

US drug delivery product demand will rise 7.4 percent yearly to $134 billion in 2015. Parenteral products will grow the fastest, led by monoclonal antibodies and polymer-encapsulated medicines. Other types expected to do well include prefilled dry powder and metered dose brachytherapy implants, and implantable drug delivery products.

This study analyzes the $93.8 billion US drug delivery system industry. It presents historical demand data for the years 2000, 2005 and 2010, and forecasts for 2015 and 2020 by excipient (e.g., polymers, cellulose, minerals), product type (e.g., oral, parenteral, inhalation, implantable, transdermal) and application (e.g., central nervous system, respiratory, hormones, gastrointestinal).

The study also considers market environment factors, details industry structure, evaluates company market share and profiles 27 industry players, including Roche, GlaxoSmithKline and Becton Dickinson.

Table of Contents

INTRODUCTION

I. EXECUTIVE SUMMARY

II. MARKET ENVIRONMENT

  • General
  • Economic Factors
  • Demographic Patterns
  • Health Care Trends
    • Health Insurance
    • Medical Conditions
      • Acute Conditions
      • Chronic Conditions
    • National Health Expenditures
    • Medical Providers
      • Hospitals
      • Skilled Nursing Homes
      • Outpatient Facilities
      • Physicians
    • Patient Activity
      • Hospital Activity
      • Surgical Procedures
      • Outpatient Consultations
  • Pharmaceutical Market Overview
    • Regulation
    • Research & Development
    • Demand Patterns
      • Therapeutic Classes
      • Dosage Formulations
      • Distribution Classification
      • Commercial Status

III. DRUG DELIVERY EXCIPIENTS

  • General
  • Polymers
    • Polyethylene Glycol
    • Acrylic Polymers
      • Carbomers
      • Methacrylate Copolymers
    • Polyethylene Oxide
    • Polyvinyl Alcohol
    • Other Synthetic Polymers
  • Cellulose Excipients
    • Ethyl Cellulose
    • Hydroxypropyl Methylcellulose (HPMC)
    • Other Cellulose Excipients
  • Minerals
    • Mineral Hydrocarbons
      • Petrolatum
      • Mineral Oil
      • Waxes
    • Other Minerals
      • Attapulgite
      • Calcium Carbonate
      • Calcium Silicate
      • Electrolytes
  • Other Excipients
    • Sterile & Purified Waters
    • Starch Compounds
      • Cyclodextrins
      • Dextrates
      • Dextrin
      • Maltodextrin
    • Sugars & Polyols
      • Sucrose
      • Sorbitol
      • Lactose
      • Mannitol
    • Natural Gums
    • All Other Excipients

IV. DRUG DELIVERY PRODUCTS OVERVIEW

  • General
  • Types of Drug Delivery Products
  • Historical Market Trends
  • Regulation
  • Research & Development
  • US Trade
  • International Markets

V. ORAL DRUG DELIVERY PRODUCTS

  • General
  • Controlled-Release Formulations
    • Coated Products
    • Diffusion Products
    • Reservoir Products
  • Chewable Tablets
  • Nanoparticulate Formulations
  • Orally Disintegrating Tablets (ODT)
  • Transmucosal Formulations

VI. PARENTERAL DRUG DELIVERY PRODUCTS

  • General
  • Therapeutic Monoclonal Antibodies
    • Types of Monoclonal Antibodies
    • Marketed Products
    • Therapeutic Monoclonal Antibodies in Development
  • Encapsulated Parenteral Drug Delivery Products
    • Polymer-Protected Products
      • PEG-Based Parenteral Therapies
      • Other Polymer-Protected Parenteral Therapies
      • Developmental Activities
    • Liposomes
      • Marketed Products
      • Developmental Activities
  • Infusion Products
    • IV Administration Sets
    • Premixed IV Solutions
    • Infusion Pumps
    • Other Infusion Products
      • Enteral Feeding Supplies
      • IV Accessories
  • Parenteral Drug Delivery Devices
    • Prefillable Syringes
      • Injectors
      • Cartridges
    • Hypodermic Syringes
    • IV Catheters
    • Other Parenteral Delivery Devices

VII. OTHER DRUG DELIVERY PRODUCTS

  • General
  • Inhalation Drug Delivery Products
    • Dry Powder Formulations
      • Types of DPIs
      • Developmental Activities
    • Metered Dose Formulations
      • 3M Drug Delivery Systems
      • Other Producers
  • Implantable Drug Delivery Products
    • Drug-Eluting Stents
    • Other Implantable Drug Delivery Products
      • Drug Inserts
      • Brachytherapy
      • Drug Pumps
  • Transdermal Drug Delivery Products
    • Transdermal Technologies
    • Central Nervous System Agents
    • Other Transdermal Therapies
      • Hormones & Related Agents
      • OXYTROL 195
      • Cardiovascular Agents
      • Nicotine Patches
      • Scopolamine

VIII. APPLICATIONS

  • General
  • Central Nervous System Agents
  • Respiratory Agents
  • Hormones & Related Agents
  • Gastrointestinal Agents
  • Cardiovascular Agents
  • Anti-Infective Agents
  • Nutritional Agents
  • Genito-Urinary Agents
  • Other Pharmaceuticals

IX. INDUSTRY STRUCTURE

  • General
  • Market Share
  • Competitive Strategies
  • Mergers & Acquisitions
  • Licensing & Related Agreements
  • Marketing & Distribution
  • Manufacturing

Company Profiles

  • Abbott Laboratories
  • Amgen Incorporated
  • Aptalis Pharma Incorporated
  • AptarGroup Incorporated
  • AstraZeneca plc
  • Aveva Drug Delivery Systems, see Nitto Denko
  • Axcan Intermediate Holdings, see Aptalis Pharma
  • Baxa, see Baxter International
  • Baxter International Incorporated
  • Becton, Dickinson and Company
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Braun (B.) Melsungen AG
  • Bristol-Myers Squibb Company
  • Cephalon, see Teva Pharmaceutical Industries
  • Conor Medsystems, see Johnson & Johnson
  • Cordis, see Johnson & Johnson
  • Eurand, see Aptalis Pharma
  • Evonik Industries AG
  • Facet Biotech, see Abbott Laboratories
  • Genentech, see Roche Holding
  • Genzyme, see Sanofi-Aventis
  • GlaxoSmithKline plc
  • Hospira Incorporated
  • ImClone Systems, see Lilly (Eli)
  • Janssen Pharmaceuticals, see Johnson & Johnson
  • Johnson & Johnson
  • Lilly (Eli) and Company
  • Medingo, see Roche Holding
  • Merck & Company Incorporated
  • Nitto Denko Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Ortho-McNeil-Janssen Pharmaceuticals, see Johnson & Johnson
  • Pfizer Incorporated
  • Roche Holding Limited
  • Sanofi-Aventis
  • Teva Pharmaceutical Industries Limited
  • 3M Company
  • Unilife Corporation
  • West Pharmaceutical Services Incorporated

LIST OF TABLES

SECTION I -- EXECUTIVE SUMMARY

  • Summary Table

SECTION II -- MARKET ENVIRONMENT

  • 1 Macroeconomic Indicators
  • 2 Population by Age Group
  • 3 Health Insurance Coverage of the US Population
  • 4 Acute Conditions by Type
  • 5 Chronic Conditions by Type
  • 6 National Health Expenditures by Type
  • 7 Medical Providers by Type
  • 8 Patient Activity by Type & Volume
  • 9 Pharmaceutical Demand by Therapeutic Class
  • 10 Pharmaceutical Demand by Dosage Formulation
  • 11 Pharmaceutical Demand by Distribution Classification
  • 12 Pharmaceutical Demand by Commercial Status

SECTION III -- DRUG DELIVERY EXCIPIENTS

  • 1 Drug Delivery Excipient Demand by Product Group
  • 2 Polymer Drug Delivery Excipient Demand by Type
  • 3 Cellulose Drug Delivery Excipient Demand by Type
  • 4 Mineral Drug Delivery Excipient Demand by Type
  • 5 Other Drug Delivery Excipient Demand by Type

SECTION IV -- DRUG DELIVERY PRODUCTS OVERVIEW

  • 1 Drug Delivery Product Demand by Dosage Formulation
  • 2 Drug Delivery Product Demand, 2000-2010
  • 3 US Trade in Drug Delivery Products
  • 4 World Drug Delivery Product Demand by Region

SECTION V -- ORAL DRUG DELIVERY PRODUCTS

  • 1 Oral Drug Delivery Product Demand by Type
  • 2 Oral Controlled-Release Drug Delivery Product Demand by Type, Mode of Action & Application
  • 3 Oral Coated Drug Delivery Product Demand
  • 4 Oral Diffusion Drug Delivery Product Demand
  • 5 Oral Reservoir Drug Delivery Product Demand
  • 6 Chewable Tablet Demand by Therapeutic Class
  • 7 Oral Nanoparticulate Product Demand by Application
  • 8 Orally Disintegrating Tablet (ODT) Demand by Application
  • 9 Transmucosal Product Demand

SECTION VI -- PARENTERAL DRUG DELIVERY PRODUCTS

  • 1 Parenteral Drug Delivery Product Demand by Type
  • 2 Therapeutic Monoclonal Antibody Demand by Application
  • 3 Therapeutic Monoclonal Antibodies Approved for US Sale
  • 4 Encapsulated Parenteral Product Demand by Type & Application 136
  • 5 Infusion Product Demand by Type
  • 6 Parenteral Delivery Device Demand by Type

SECTION VII -- OTHER DRUG DELIVERY PRODUCTS

  • 1 Other Drug Delivery Product Demand by Type
  • 2 Inhalation Drug Delivery Product Demand by Type
  • 3 Dry Powder Inhaler (DPI) Product Demand
  • 4 Metered Dose Inhaler (MDI) Product Demand
  • 5 Implantable Drug Delivery Product Demand by Type & Application
  • 6 Drug-Eluting Stent Demand 180
  • 7 Other Implantable Drug Delivery Product Demand by Type
  • 8 Transdermal Product Demand by Application

SECTION VIII -- APPLICATIONS

  • 1 Drug Delivery Product Demand by Application
  • 2 Central Nervous System (CNS) Drug Delivery Product Demand by Type
  • 3 Respiratory Drug Delivery Product Demand by Type
  • 4 Hormone & Related Drug Delivery Product Demand by Type
  • 5 Gastrointestinal Drug Delivery Product Demand by Type
  • 6 Cardiovascular Drug Delivery Product Demand by Type
  • 7 Anti-Infective Drug Delivery Product Demand by Type
  • 8 Nutritional Drug Delivery Product Demand by Type
  • 9 Genito-Urinary Drug Delivery Product Demand by Type
  • 10 Drug Delivery Product Demand in Other Pharmaceuticals by Type

SECTION IX -- INDUSTRY STRUCTURE

  • 1 US Drug Delivery Product Sales by Company, 2010
  • 2 Selected Acquisitions & Divestitures
  • 3 Selected Cooperative Agreements

LIST OF CHARTS

SECTION IV -- DRUG DELIVERY PRODUCTS OVERVIEW

  • 1 Drug Delivery Product Demand by Dosage Formulation, 2010

SECTION V -- ORAL DRUG DELIVERY PRODUCTS

  • 1 Oral Drug Delivery Product Demand by Type, 2010
  • 2 Oral Controlled-Release Drug Delivery Product Demand by Type, 2010

SECTION VI -- PARENTERAL DRUG DELIVERY PRODUCTS

  • 1 Parenteral Drug Delivery Product Demand by Type, 2010

SECTION VII -- OTHER DRUG DELIVERY PRODUCTS

  • 1 Other Drug Delivery Product Demand by Type, 2010

SECTION VIII -- APPLICATIONS

  • 1 Drug Delivery Product Demand by Application, 2010

SECTION IX -- INDUSTRY STRUCTURE

  • 1 Drug Delivery Dosage Formulations, US Market Share, 2010
  • 2 Drug Delivery Devices, US Market Share, 2010
Back to Top